Bright Peak Therapeutics raises €81.0M Series C round
11 June 2024· Basel, Switzerland· health, biotechnology, protein_engineering, drug_discovery, b2b
To advance BPT567 into a Phase 1/2a clinical trial and accelerate a pipeline of next-generation immunotherapies, specifically to develop new immunotherapy treatments and start clinical trials for BPT567.
Investors
LeadJohnson & Johnson Innovation – JJDC
Also participating
InvusVersant VenturesFidelity Management & Research CompanyQatar Investment AuthorityAlexandria Venture Investmentsundisclosed leading healthcare investment fundVenrockKB InvestmentNorthleaf Capital PartnersRA Capital Management
About Bright Peak Therapeutics
Stage
Series C
Headquarters
Basel, Switzerland
Founded
2017
Team Size
51–200
Sectors
healthbiotechnologyprotein_engineeringdrug_discoveryb2b